HPV and Head & Neck Cancer Symposium, 17 May, 2013
Speaker Biography

Dr. Linda Sharp, PhD (Epidemiologist, National Cancer Registry Ireland) is the senior epidemiologist at the Republic of Ireland's agency for collecting information on all cancer cases. Dr. Sharp has been actively involved in HPV research for over 10 years and is a key figure in promoting HPV-related head and neck cancer research on the island of Ireland.

http://www.ncbi.nlm.nih.gov/pubmed/22862968






Dr. Michael O'Rorke, PhD, is a postdoctoral research fellow from the Centre of Public Health, Queen’s University Belfast. Dr O’Rorke’s training to date has been in the field of cancer epidemiology and pharmacoepidemiology allied to the study of cancer progression, but he has previously published on HPV infection and cervical cancer as well as conducting a recent meta-analysis of HPV related head and neck cancer survival.
http://www.ncbi.nlm.nih.gov/pubmed/22841677

 

 

Prof. John O'Leary (Pathologist, Trinity College Dublin) is a consultant histopathologist at St. James's Hospital and Director of Pathology at the Coombe Women and Infants University Hospital. During his career, Prof. O'Leary has made several key findings specifically in the areas of cervical cancer and ovaraian cancer and has an international reputation in cancer medicine. Prof. O'Leary heads a multi-investigator group at the Institute of Molecular Medicine in Trinity focussing on the molecular characterisation of several cancer systems including head and neck cancer.
http://www.ncbi.nlm.nih.gov/pubmed/22235204


Dr. William Westra, MD is a Professor of Pathology, Oncology and Otolaryngology/ Head and Neck Surgery at the Johns Hopkins University School of Medicine. Dr. Westra currently practices surgical pathology with a subspecialty interest in head and neck pathology. He is the Co-Director of Surgical Pathology and Director of Head and Neck Pathology Consultation Service at Johns Hopkins. He is also a member of the highly successful head and neck cancer research team at Johns Hopkins. This team has been responsible for many of the fundamental advances made in our understanding of head and neck cancer over the last decade including the work that has established HPV as an important cause of a subset of head and neck cancers. He is a world authority on HPV-related head and neck cancer, and his work is focused on the detection of HPV in clinical samples. He has authored numerous peer-reviewed articles.
http://pathology.jhu.edu/department/services/consults/head-neck.cfm




Dr Helena Rowley is a consultant Otolaryngologist/Head and Neck Surgeon at the Mater University Hospital and Children's University Hospital, Dublin. Dr. Rowley is a Galway graduate who has a keen interest in surgery and conditions affecting the head and neck region in adults and children. Dr. Rowley did her MD thesis in Liverpool on Molecular biology markers in Head and Neck Cancer. She subsequently did clinical Fellowships at Johns Hopkins, Baltimore and in Boston. Prior to returning to Ireland, Dr. Rowley held a consultant post in Head and Neck Surgery in Liverpool.








Dr. Sara Pai, MD PhD serves as an Associate Professor of Otolaryngology, Head and Neck Surgery and Oncology at the Johns Hopkins University School of Medicine. Dr. Pai research interests include the development of novel cancer vaccines for HPV-associated head and neck cancers and understanding how cancer cells can alter their microenvironment to evade the immune system. She is the guest editor for the Otolaryngologic clinics of North America recent supplement entitled: "HPV and Head and Neck Cancer" and has organized conferences in Baltimore on this topic.
http://www.hopkinsmedicine.org/otolaryngology/our_team/faculty/pai.html





Dr. Mererid Evans (Consultant Clinical Oncologist, Velindre Cancer Centre) specialises in the management of patients with head and neck cancer. Dr. Evans has worked with members of the HPV research laboratory at Cardiff University to establish the true prevalence of HPV-related head and neck cancer in Wales and is currently collaborating with head and neck surgical colleagues across the UK to develop new adjuvant treatment protocols for HPV-positive oropharyngeal cancer. Other research interests includes optimization of the use of PET for head and neck cancer radiotherapy planning.
http://www.ncbi.nlm.nih.gov/pubmed/20584591



Prof. Terry Jones BSc (Hons), FRCS (ORL-HNS), MD is a Professor of Head and Neck Surgery at the CR-UK Centre, University of Liverpool. He is the co-founder of the Mersey Head and Neck Oncology Research Group (MHNORG), a member of the National Cancer Research Institute (H&N) Clinical Studies Group and the Surgery and Local treatments sub-committee, an editor for the Cochrane ENT Disorders Group and local lead for the NIHR ORL-HNS Specialty Group. In addition, He sits on the CR-UK Clinical Trials Awards and Advisory Committee. He is the Chief Investigator for two national CR-UK funded Head and Neck studies: REALISTIC and HPV.UK.

 

http://www.liverpoolcancercentre.org.uk/content/staff/jones.asp

http://www.bmj.com/content/340/bmj.c1439?view=long&pmid=20339160


Mr. James Paul O'Neill MD MBA is an ENT surgeon at the Mater Misericordiae University Hospital, Dublin. Mr. O'Neill has specialized in Head, Neck and Skull Base surgery. He recently completed a two year Fellowship at Memorial Sloan Kettering Cancer Center (MKSCC) in New York. Mr. O'Neill has an MD in Thyroid Cancer and publications on all aspects of Head and Neck Cancer Care. In recent times, he conducted a HPV analysis of the 'Unknown Primary' at MKSCC with Dr. Dennis Kraus.
http://www.ncbi.nlm.nih.gov/pubmed/20519038


Prof. Kevin Frick, PhD is a Professor of Health Economics in the Department of Health Policy & Management, Johns Hopkins School of Public Health. Prof Frick combines his knowledge of economic analysis with clinical and epidemiological insights from his colleagues to produce cost-effectiveness analyses that bring the tools of economic decision making to policy-makers. He has published many papers on costing methodologies, cancer survivorship and the economic burden of HPV-head and neck cancer in the United States.

http://www.jhsph.edu/faculty/directory/profile/903/Frick/Kevin



Dr. Deidre Hollingsworth, PhD is an Infectious Disease Epidemiologist & Mathematical Modeller at the University of Warwick. Dr. Hollingsworth was previously a member of the MRC Centre for Outbreak Analysis and Modelling at Imperial College London before taking up her current role. Dr. Hollingsworth has worked on modelling sexually transmitted diseases (e.g. HIV) and has written eloquently about how models inform public policy.
http://www.ncbi.nlm.nih.gov/pubmed/19806073





Dr. Ruth Chapman, PhD is a Mathematical Modeller at United Biosource Corporation, London. Dr. Chapman previously worked with the Health Protection Agency (HPA) in the UK and the London School of Hygiene and Tropical Medicine. She has published a number of empirical papers on the topic of HPV vaccination and is well-place to discuss the merits of vaccinating boys.
http://www.bmj.com/content/343/bmj.d5775



Dr. Brenda Corcoran (Consultant in Public Health Medicine, HSE National Immunisation Office) along with Dr. Helena Murray, Senior Medical Officer, are responsible for the planning and implementation of all national immunisation programmes including the HPV vaccination programme. She is a member of the National Immunisation Advisory Committee. Dr. Corcoran will discuss the decision making process for the implementation of HPV vaccination programme in Ireland and review recommendations in other countries.
http://www.immunisation.ie/en/Whoweare/